AXIM® Biotech Expands Patent Protection on Cannabinoid Chewing Gum
November 17, 2016 1:11 pm ET
AXIM® Biotechnologies Inc. (OTCQB: AXIM), a leader in hemp-based cannabinoid research and development, recently announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for Patent 9,433,601 covering the use of all cannabinoids in cannabinoid-containing controlled-release chewing gum products. The patent represents an extension of its existing Patent 9,023,322 covering medicinal, functional chewing gum as a delivery mechanism for cannabidiol (CBD).
In this article, we will take a closer look at the company’s new patent and the potential for its technology over the coming quarters and years.
New Delivery Mechanism
Chewing gum represents an innovative delivery mechanism with proven benefits. For example, nicotine gum has been used for years as a preferred release mechanism that enables users to carefully control dosing over time. Smokers may only experience cravings at certain times and they can satisfy those cravings with chewing gum rather than receiving a steady dose of nicotine over time that may or may not be needed with patches.
Tetrahydrocannabinol – or THC – has similar issues with dosing across patient populations. The right amount of THC depends largely on an individual’s metabolism and experience, which means that chewing gum could be a great way to control dosing relative to patches that deliver a constant dose. Chewing gum also enables individuals to achieve an extended and controlled release of THC or other cannabinoids, which may not be possible with edibles or smoke-able mechanisms.
The act of mastication (chewing) has its own benefits that are not present in other delivery formats. For example, it is well researched that the act of chewing has neuroprotective properties such as increase of blood flow through the middle cerebral artery, and the release of “reward” hormones such as dopamine, serotonin and acetylcholine. It improves the short- and long-term memory and concentration and reduces stress by providing a eustress condition. It also shortens the pituitary supra-renal axis. The act of chewing also is a form of a physical exercise that addresses the sedentary life style of the majority of the population in the industrialized world and especially those with neurodegenerative diseases. In short, AXIM’s delivery system is the only one of its kind where 1+1 equals more than 2.
AXIM® Biotechnologies’ new patent expands its patent protection from just CBD to at least 85 different cannabinoid compounds found in the cannabis plant – including THC. The patent could become increasingly valuable over time as research confirms the potential for various cannabinoids to treat medical conditions ranging from chronic pain to cancer. The company holds the exclusive rights to use chewing gum as a delivery mechanism for these treatments.
Growing Product Portfolio
AXIM® Biotechnologies’ initial product was CanChew®. It is being developed as a botanical hemp-derived CBD chewing gum with a unique oral mucosal absorbance delivery system. The innovative gum is non-habit forming and can be acquired without a prescription in all 50 states since it is hemp-derived and doesn’t include any psychoactive components. Early adopters may acquire the initial product, generating revenue as clinical products are developed.
The company plans to initiate clinical trials for its combination CBD/THC gum, MedChew® Rx, for the treatment of pain and spasticity associated with multiple sclerosis. Based on sublingually delivered cannabinoid-based products that are already on the market, MedChew® Rx is addressing a market that is worth some $4.8 billion and would be fully registered with the EMA and FDA if approved, creating a significant catalyst for investors.
Figure 1 – AXIM® Biotechnologies Inc. Pipeline – Source: AXIM® Biotechnologies Website
In the future, the company plans to launch many other cannabinoid-based products targeting a variety of different conditions. Its AX-1602, for example, is a first-of-its-kind product incorporating cannabigerol (CBG) for the treatment of psoriasis and atopic dermatitis. Meanwhile, CanChew® Rx is being developed on the basis of a pharmaceutical-grade 99.9% pure, crystalline, microencapsulated CBD that’s manufactured in various concentrations with markedly increased bioavailability.
AXIM® Biotechnologies Inc. represents a unique investment opportunity within the burgeoning cannabis industry. With exclusive rights to CanChew® and the chewing gum delivery mechanism for cannabinoids, the company could tap into multiple billion-dollar markets with products that address key shortcomings in existing cannabinoid delivery mechanisms – namely, the controlled release of cannabinoids into a patient’s body and improved bioavailability as well as providing unique neuroprotection based on the act of chewing.
The company has an existing product on the market and is progressing with numerous clinical programs. Over the coming quarters, the early results from these programs could provide important catalysts for the stock price.
For more information, visit the company’s website at www.aximbiotech.com.